KPRX Kiora Pharmaceuticals, Inc.
$2.65▲ +2.71%
Healthcare
Other
After hours
$2.65▲ +1.15%
Sep 11, 4:10 PM ET
Volume 10.5K
Avg Volume (10D) 10.1K
Key Metrics & Fundamentals
Market Cap
$11.72M
P/E Ratio
–
Div Yield
–%
52W Range
1.77 - 2.95
% vs 50 MA
3.17%
% vs 200 MA
13.22%
RSI-14
55.8
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.04
Free Cash Flow
-$1.92M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$2.02M
COGS
–
Operating Exp
$2.12M
Operating Income
-$2.12M
EBIT
-$2.12M
Pretax Income
-$2.08M
Net Income
-$2.08M
EPS (Diluted)
-0.34
Price & Volume History
Loading chart…
Recent News
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
TMX Newsfile · Sep 8, 2026 11:00 AM
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
TMX Newsfile · Aug 19, 2026 11:00 AM
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
TMX Newsfile · Aug 7, 2026 11:00 AM
SS Innovations International (SSII) Appoints Sarah Romano as Chief Financial Officer
NewMediaWire · Jul 15, 2026 6:25 PM
SS Innovations names Sarah Romano as CFO
MedTech Dive · Jul 15, 2026 5:03 AM
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
TMX Newsfile · Jul 2, 2026 11:00 AM
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
TMX Newsfile · Jun 18, 2026 11:00 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See KPRX's money flow as a full page
Social Sentiment
No Reddit posts found for KPRX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.